The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...

Scancell is responsible for the clinical and regulatory development, as well as commercialisation of the combined product.

PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA ...

FluMist is the only nasal flu vaccine, but it is not new. The FDA approved it in 2003 for people 5 to 49 years old before ...

The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...

In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration.

The PharmaJet Needle-free Delivery System has shown effective uptake of the SCIB1 DNA vaccine in addition to offering speed, convenience, and enhanced patient experience. PharmaJet is eligible to ...

The FDA approved FluMist for self- or caregiver-administration, making it the first influenza vaccine that does not need to ...

In a first, the Food and Drug Administration on Friday approved AstraZeneca's FluMist, a nasal spray flu vaccine that anyone ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

A phase II trial for patients with traumatic brain injury (TBI) will aim to break the impasse of 30 years of failed clinical ...